Envestnet Asset Management Inc. Buys New Holdings in SPDR S&P Pharmaceuticals ETF $XPH

Envestnet Asset Management Inc. purchased a new position in shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 223,866 shares of the company’s stock, valued at approximately $10,732,000. Envestnet Asset Management Inc. owned about 6.05% of SPDR S&P Pharmaceuticals ETF at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. First Citizens Bank & Trust Co. increased its stake in shares of SPDR S&P Pharmaceuticals ETF by 2.9% in the third quarter. First Citizens Bank & Trust Co. now owns 181,429 shares of the company’s stock worth $8,698,000 after acquiring an additional 5,038 shares during the period. Envestnet Portfolio Solutions Inc. boosted its holdings in SPDR S&P Pharmaceuticals ETF by 6.7% in the third quarter. Envestnet Portfolio Solutions Inc. now owns 171,930 shares of the company’s stock valued at $8,242,000 after purchasing an additional 10,842 shares during the last quarter. Goldman Sachs Group Inc. grew its position in SPDR S&P Pharmaceuticals ETF by 96.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 119,929 shares of the company’s stock worth $5,253,000 after purchasing an additional 59,007 shares during the period. JPMorgan Chase & Co. raised its stake in shares of SPDR S&P Pharmaceuticals ETF by 9.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 57,258 shares of the company’s stock valued at $2,324,000 after buying an additional 4,918 shares during the last quarter. Finally, SVB Wealth LLC raised its stake in shares of SPDR S&P Pharmaceuticals ETF by 24.5% during the 2nd quarter. SVB Wealth LLC now owns 41,012 shares of the company’s stock valued at $1,664,000 after buying an additional 8,079 shares during the last quarter.

SPDR S&P Pharmaceuticals ETF Stock Down 0.2%

Shares of XPH opened at $57.40 on Thursday. The company has a market capitalization of $298.48 million, a price-to-earnings ratio of 14.28 and a beta of 0.60. SPDR S&P Pharmaceuticals ETF has a 52 week low of $35.22 and a 52 week high of $58.14. The stock’s 50-day moving average price is $56.42 and its 200-day moving average price is $51.36.

About SPDR S&P Pharmaceuticals ETF

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.